15 Jul 2024
// PRESS RELEASE
21 Jun 2024
// PRESS RELEASE
05 Jun 2024
// PRESS RELEASE
Latest Content by PharmaCompass
Douglas CDMO develops, manufactures, and packs various dosage forms, and provides regulatory support for international distribution.
About
CPhI Worldwide, MilanCPhI Worldwide, Milan
Industry Trade Show
Booth #22A18
08-10 October, 2024
Bio-Europe 2024Bio-Europe 2024
Industry Trade Show
Attending
04-06 November, 2024
American Pharma SummitAmerican Pharma Summit
Industry Trade Show
Attending
18-19 November, 2024
CONTACT DETAILS
Events
Webinars & Exhibitions
CPhI Worldwide, MilanCPhI Worldwide, Milan
Industry Trade Show
Booth #22A18
08-10 October, 2024
Bio-Europe 2024Bio-Europe 2024
Industry Trade Show
Attending
04-06 November, 2024
American Pharma SummitAmerican Pharma Summit
Industry Trade Show
Attending
18-19 November, 2024
CORPORATE CONTENT #SupplierSpotlight
https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-novo-s-parent-buys-catalent-for-us-16-5-bn-fujifilm-merck-kgaa-axplora-lonza-expand-capabilities
15 Jul 2024
// PRESS RELEASE
https://www.douglascdmo.com/insights/articles/the-regulatory-edge-of-new-zealand
21 Jun 2024
// PRESS RELEASE
https://www.douglascdmo.com/insights/articles/smart-softgels-innovation-in-pharma
05 Jun 2024
// PRESS RELEASE
https://www.douglascdmo.com/insights/articles/a-guide-on-cro-cmo-and-cdmo-partnerships
16 May 2024
// PRESS RELEASE
https://www.douglascdmo.com/insights/articles/a-personalized-approach-as-a-privately-owned-cdmo
26 Apr 2024
// PRESS RELEASE
26 Apr 2024
// PRESS RELEASE
Details:
R-107, an oral extended-release dose of racemic ketamine being developed as add-on or monotherapy for treatment resistant depression (TRD). It has demonstrated a significant antidepressant effect with maintenance of response at 3 months, high compliance dosing.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: R-107
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2023
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Douglas Pharmaceuticals Announces Formation of Clinical Advisory Board for Lead Program R-107
Details : R-107, an oral extended-release dose of racemic ketamine being developed as add-on or monotherapy for treatment resistant depression (TRD). It has demonstrated a significant antidepressant effect with maintenance of response at 3 months, high compliance ...
Brand Name : R-107
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 26, 2023
Details:
Upsher-Smith's product is AB2-rated to the branded product, Absorica® (isotretinoin) capsules. Isotretinoin capsules are a generic version of ABSORICA® indicated for the treatment of severe recalcitrant nodular acne.
Lead Product(s): Isotretinoin
Therapeutic Area: Dermatology Brand Name: Isotretinoin-Generic
Study Phase: ApprovedProduct Type: Small molecule
Recipient: Upsher-Smith Laboratories
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2021
Lead Product(s) : Isotretinoin
Therapeutic Area : Dermatology
Highest Development Status : Approved
Recipient : Upsher-Smith Laboratories
Deal Size : Not Applicable
Deal Type : Not Applicable
Upsher-Smith Launches Isotretinoin Capsules
Details : Upsher-Smith's product is AB2-rated to the branded product, Absorica® (isotretinoin) capsules. Isotretinoin capsules are a generic version of ABSORICA® indicated for the treatment of severe recalcitrant nodular acne.
Brand Name : Isotretinoin-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 25, 2021
Details:
R-107 (extended-release oral dose of ketamine) act as a blocks the NMDA receptor and it is investigated for the treatment of treatment resistant depression.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: R-107
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2021
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Trial Data Suggests Major Breakthrough in Treatment Resistant Depression
Details : R-107 (extended-release oral dose of ketamine) act as a blocks the NMDA receptor and it is investigated for the treatment of treatment resistant depression.
Brand Name : R-107
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 15, 2021
Services
Packaging
Drug Product Manufacturing
API & Drug Product Development
Inspections and registrations
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?